Soluble Integrin Beta3 Capture Reagent for Anti-HPA-1a Antibody Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying and determining the potency of anti-HPA-1a antibodies are hindered by the instability of platelets in vitro and the unavailability of a stable, soluble form of HPA-1a antigen, leading to reproducibility and sensitivity issues in assays for diagnosing and treating fetal neonatal alloimmune thrombocytopenia.
Innovation Solution
A method using a modified integrin β3 as a capture reagent, which binds to anti-HPA-1a antibodies, allowing for the formation of a detection complex that can be measured to quantify and assess the potency of anti-HPA-1a antibodies in samples, utilizing a detectable label and a detecting reagent to enhance sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the MAIPA assay uses human platelets as the source of HPA antigens, then the assay can detect anti-HPA-1a antibodies, but the platelets are unstable in vitro and show inherent variability
Solution Approach 1:
The patent creates a soluble copy of the HPA-1a antigen by expressing the integrin β3 subunit containing the HPA-1a epitope in a heterologous system (CHO cells). This soluble recombinant antigen replicates the essential binding properties of the native platelet antigen without the instability and variability issues of primary human platelets, enabling reliable and reproducible assays.
Solution Approach 2:
The patent introduces a soluble integrin β3 subunit as an intermediary between the anti-HPA-1a antibodies and the assay system. This intermediary serves as a stable, soluble form of the antigen that mediates the detection process, replacing the need for unstable whole platelets while maintaining the specific immunological interaction required for accurate detection.
2Measurement precision
If the MAIPA assay uses monoclonal antibodies to immobilize platelet antigens, then the assay can quantify anti-platelet antibodies, but the sensitivity and reproducibility are problematic
Solution Approach 1:
The patent replaces the complex platelet antigen system with a simplified soluble copy - the recombinant integrin β3 subunit. This copy maintains the critical HPA-1a epitope while eliminating the variability of whole platelets, thereby improving both measurement precision and assay reproducibility across different laboratories and batches.
Solution Approach 2:
The patent changes the physical state of the antigen from membrane-bound (in whole platelets) to soluble form. This parameter change - from insoluble membrane protein to soluble recombinant protein - fundamentally improves assay performance by enabling better control over antigen concentration, stability, and accessibility, leading to more precise and reproducible measurements.
3Ease of manufacture
If no stable soluble form of HPA-1a is available, then the field lacks validated methods for quantifying anti-HPA-1a antibodies, but creating such a form is required for accurate potency assessment
Solution Approach 1:
The patent successfully creates a stable soluble copy of HPA-1a by expressing the integrin β3 subunit in CHO cells. This soluble recombinant antigen can be manufactured consistently with defined concentration and purity, enabling the development of validated assays for accurate potency assessment of anti-HPA-1a antibody therapeutics.
Solution Approach 2:
The soluble integrin β3 subunit serves as an intermediary that bridges the gap between the need for a manufacturable assay system and the requirement for accurate potency measurement. It provides a stable, soluble target that can be reliably produced and used to assess therapeutic antibody potency with the required precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides accurate, precise, and highly selective assays for quantifying anti-HPA-1a antibodies, enabling effective assessment of their potency and pharmacokinetics, thereby supporting the development of therapeutic products for bleeding disorders like fetal neonatal alloimmune thrombocytopenia.
Implementation Method 1
contacting the sample with a capture reagent that binds to the anti-HPA-1a antibodies to form a detection complex
Data Source
AI summary
Methods of quantifying anti-HPA-1a antibodies in a sample, comprising (a) contacting the sample with a capture reagent that binds to the anti-HPA-1a antibodies to form a detection complex, wherein the capture reagent comprises a modified integrin psi and (b) measuring an amount of the detection complex, wherein the amount of the detection complex indicates the quantity of the anti-HPA-1a antibodies in the sample. The methods may also comprise contacting the sample with a detecting reagent that binds to the anti-HPA-1a antibodies and becomes part of the detection complex. The capture reagent and/or the detecting reagent may comprise a detection label, in which measuring the amount of the detection complex comprises measuring the amount of the detectable label.